NCT02466828View on ClinicalTrials.gov

qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia.

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
GlioblastomaHypoxia
Interventions
DRUG

Feraheme®

Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.

Trial Locations (2)

M4N 3M5

Sunnybrook Health Sciences Centre, Toronto

M5B 1W8

St. Michael's Hospital, Toronto

All Listed Sponsors
collaborator

Unity Health Toronto

OTHER

lead

Sunnybrook Health Sciences Centre

OTHER

NCT02466828 - qBOLD MRI of Glioblastoma Multiforme for Assessment of Tumor Hypoxia. | Biotech Hunter | Biotech Hunter